{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:14:08Z","timestamp":1760058848920,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Physician-Scientist Program of Heidelberg University, Faculty of Medicine","award":["DE 614\/16-1"],"award-info":[{"award-number":["DE 614\/16-1"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation DFG","doi-asserted-by":"publisher","award":["DE 614\/16-1"],"award-info":[{"award-number":["DE 614\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Stereotactic body radiotherapy is frequently used in patients with adrenal metastases. Motion of adherent radiosensitive organs at risk (OARs) and tumors influence OAR toxicity and tumor control. Online-adaptive Magnetic Resonance-guided radiotherapy (MRgRT) can address and mitigate interfractional changes. However, the impact of intrafractional variations in adrenal MRgRT is unknown. Methods: A total of 23 patients with 24 adrenal metastases were treated with MRgRT. After daily plan adaptation and before beam application, an additional (preRT) 3d MRI was acquired. PreRT target volumes and OARs were retrospectively recontoured in 200 fractions. The delivered, online-adapted treatment plans, as well as non-adapted baseline plans, were calculated on these re-contoured structures to quantify the dosimetric impact of intrafractional variations on target volume coverage and OAR doses with and without online adaptation. Normal tissue complication probabilities (NTCPs) were calculated. Results: The median time between the two MRIs was 56.4 min. GTV and PTV coverage (dose to 95% of the PTV, D95%, and volume covered by 100% of the prescription dose, V100%) were significantly inferior in the preRT plans. GTV Dmean was significantly impaired in left-sided metastases, but not in right-sided metastases. Compared to non-adapted preRT plans, adapted preRT plans were still significantly superior for all GTV and PTV metrics. Intrafractional violations of OAR constraints were frequent. D0.5cc and the volume exposed to the near-maximum dose constraint were significantly higher in the preRT plans. The volume exposed to the D0.5cc constraints in single fractions escalated up to 1.5 cc for the esophagus, 3.2 cc for the stomach, 5.3 cc for the duodenum and 7.3 cc for the bowel. This led to significantly elevated NTCPs for the stomach, bowel and duodenum. Neither PTV D95%, nor gastrointestinal OAR maximum doses were significantly impaired by longer fraction duration. Conclusions: Intrafractional motion in adrenal MRgRT caused significant impairment of target volume coverage (D95% and V100%), potentially undermining local control. Frequent violation of gastrointestinal OAR constraints led to elevated NTCP. Compared to non-adaptive treatment, online adaptation still highly improved GTV and PTV coverage.<\/jats:p>","DOI":"10.3390\/cancers17091533","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:10:32Z","timestamp":1746076232000},"page":"1533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrafractional Motion in Online-Adaptive Magnetic Resonance-Guided Radiotherapy of Adrenal Metastases Leads to Reduced Target Volume Coverage and Elevated Organ-at-Risk Doses"],"prefix":"10.3390","volume":"17","author":[{"given":"Philipp","family":"Hoegen-Sa\u00dfmannshausen","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias P.","family":"Hartschuh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Katharina","family":"Renkamp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Buchele","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"},{"name":"Department of Radiation Oncology, RKH Klinikum Ludwigsburg, 71640 Ludwigsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Schl\u00fcter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Sandrini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-7090","authenticated-orcid":false,"given":"Fabian","family":"Weykamp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-9581","authenticated-orcid":false,"given":"Eva","family":"Meixner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-4811","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany"},{"name":"Department of Radiation Oncology, Heidelberg Ion Beam Therapy Center (HIT), Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-3444","authenticated-orcid":false,"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital, 69210 Heidelberg, Germany"},{"name":"Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany"},{"name":"National Center for Tumor Diseases (NCT), 69210 Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69210 Heidelberg, Germany"},{"name":"Department of Radiation Oncology, D\u00fcsseldorf University Hospital, 40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Cao, Y., Kashani, R., Lawrence, T.S., and Balter, J.M. (2022). Real-time prediction of stomach motions based upon gastric contraction and breathing models. Phys. Med. Biol., 68.","DOI":"10.1088\/1361-6560\/ac9660"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semradonc.2023.10.008","article-title":"Intrafraction Motion Management With MR-Guided Radiation Therapy","volume":"34","author":"Fast","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2018.06.002","article-title":"Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases","volume":"102","author":"Palacios","year":"2018","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2021.07.026","article-title":"Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy","volume":"163","author":"Chen","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2021.11.024","article-title":"CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy","volume":"166","author":"Rodriguez","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_11","first-page":"100567","article-title":"Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk","volume":"39","author":"Hoegen","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1088\/0031-9155\/56\/15\/012","article-title":"Towards MRI-guided linear accelerator control: Gating on an MRI accelerator","volume":"56","author":"Crijns","year":"2011","journal-title":"Phys. Med. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2022.07.007","article-title":"MR-guided beam gating: Residual motion, gating efficiency and dose reconstruction for stereotactic treatments of the liver and lung","volume":"174","author":"Ehrbar","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S900","DOI":"10.1016\/j.ijrobp.2014.05.2559","article-title":"Duty Cycle Selection of Gating in Lung SBRT With Flatting Filter\u2013Free Beams","volume":"90","author":"Wu","year":"2014","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00066-020-01578-z","article-title":"First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany","volume":"196","author":"Katayama","year":"2020","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/acm2.13030","article-title":"Quantitative analysis of MRI-guided radiotherapy treatment process time for tumor real-time gating efficiency","volume":"21","author":"Placidi","year":"2020","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phro.2021.07.006","article-title":"Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance-linac system using abdominal compression","volume":"19","author":"Tyagi","year":"2021","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rusu, D.N., Cunningham, J.M., Arch, J.V., Chetty, I.J., Parikh, P.J., and Dolan, J.L. (2023). Impact of intrafraction motion in pancreatic cancer treatments with MR-guided adaptive radiation therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1298099"},{"key":"ref_19","first-page":"100576","article-title":"Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer","volume":"39","author":"Uchinami","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/j.ijrobp.2022.07.2293","article-title":"Dosimetric Impact of Gastrointestinal Tract Variability during Online Adaptive MR-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas","volume":"114","author":"Teoh","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Balter, J., Dow, J., Cao, Y., Lawrence, T.S., and Kashani, R. (2023). Development of an abdominal dose accumulation tool and assessments of accumulated dose in gastrointestinal organs. Phys. Med. Biol., 68.","DOI":"10.1088\/1361-6560\/acbc61"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102682","DOI":"10.1016\/j.ejmp.2023.102682","article-title":"Impact of abdominal compression on intra-fractional motion and delivered dose in magnetic resonance image-guided adaptive radiation ablation of adrenal gland metastases","volume":"114","author":"Bernchou","year":"2023","journal-title":"Phys. Medica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13014-024-02466-x","article-title":"Intrafraction organ movement in adaptive MR-guided radiotherapy of abdominal lesions\u2014Dosimetric impact and how to detect its extent in advance","volume":"19","author":"Buchele","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0360-3016(87)90266-5","article-title":"Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms","volume":"13","author":"Lyman","year":"1987","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/0360-3016(89)90972-3","article-title":"Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method gerald","volume":"16","author":"Kutcher","year":"1989","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0360-3016(91)90172-Z","article-title":"Fitting of normal tissue tolerance data to an analytic function","volume":"21","author":"Burman","year":"1991","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nenoff, L., Sudhyadhom, A., Lau, J., Sharp, G.C., Paganetti, H., and Pursley, J. (2023). Comparing Predicted Toxicities between Hypofractionated Proton and Photon Radiotherapy of Liver Cancer Patients with Different Adaptive Schemes. Cancers, 15.","DOI":"10.3390\/cancers15184592"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: A concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejmp.2007.07.001","article-title":"A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy","volume":"23","author":"Gay","year":"2007","journal-title":"Phys. Medica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S0360-3016(03)01031-9","article-title":"Analysis of radiation-induced gastric and duodenal bleeds using the Lyman-Kutcher-Burman model","volume":"57","author":"Pan","year":"2003","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.radonc.2017.04.024","article-title":"Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data","volume":"123","author":"Holyoake","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.09.075","article-title":"A Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for Pancreatic Cancer","volume":"78","author":"Murphy","year":"2010","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ijc.34017","article-title":"Stereotactic body radiotherapy of adrenal metastases\u2014A dose-finding study","volume":"151","author":"Buergy","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_36","first-page":"100756","article-title":"Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases","volume":"46","author":"Ugurluer","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_37","first-page":"100719","article-title":"Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases","volume":"45","author":"Mills","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Michalet, M., Betta\u00efeb, O., Khalfi, S., Ghorbel, A., Valdenaire, S., Debuire, P., Aill\u00e8res, N., Draghici, R., De M\u00e9ric De Bellefon, M., and Charissoux, M. (2022). Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010291"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hoegen-Sa\u00dfmannshausen, P., Jessen, I., Buchele, C., Schl\u00fcter, F., Rippke, C., Renkamp, C.K., Weykamp, F., Regnery, S., Liermann, J., and Meixner, E. (2024). Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution. Cancers, 16.","DOI":"10.3390\/cancers16122273"},{"key":"ref_40","first-page":"100680","article-title":"Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk","volume":"43","author":"Schneiders","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijrobp.2006.12.022","article-title":"Cone-Beam Computed Tomography for On-Line Image Guidance of Lung Stereotactic Radiotherapy: Localization, Verification, and Intrafraction Tumor Position","volume":"68","author":"Purdie","year":"2007","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac","volume":"151","author":"Keizer","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kim, J.-Y., Tawk, B., Knoll, M., Hoegen-Sa\u00dfmannshausen, P., Liermann, J., Huber, P.E., Lifferth, M., Lang, C., H\u00e4ring, P., and Gnirs, R. (2024). Clinical Workflow of Cone Beam Computer Tomography-Based Daily Online Adaptive Radiotherapy with Offline Magnetic Resonance Guidance: The Modular Adaptive Radiotherapy System (MARS). Cancers, 16.","DOI":"10.3390\/cancers16061210"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yarlagadda, S., Weiss, Y., Chuong, M.D., Bassiri, N., Gutierrez, A.N., Kotecha, R., Mehta, M.P., and Mittauer, K.E. (2024). Case report: Intrafraction dose-guided tracking for gastrointestinal organ-at-risk isotoxicity delivery on an MR-guided radiotherapy system. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1357916"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1088\/0031-9155\/60\/19\/7485","article-title":"A new methodology for inter- and intrafraction plan adaptation for the MR-linac","volume":"60","author":"Kontaxis","year":"2015","journal-title":"Phys. Med. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1088\/1361-6560\/aa82ae","article-title":"Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac","volume":"62","author":"Kontaxis","year":"2017","journal-title":"Phys. Med. Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:25Z","timestamp":1760030725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091533"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091533","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}